Biopharma Moderna Inc (MRNA) has announced a $483 million government award to fund manufacturing scale-up and the development of the company’s SARS-CoV-2 vaccine mRNA-1273 to FDA licensure.The NIH-led Phase 1 study of mRNA-1273 has already completed enrollment of 3 dose cohorts (25 µg, 100 µg and 250 µg) and is now expanding to an additional 6 cohorts of older adults and elderly adultsLooking ahead, the company expects the Phase 2 study to begin in Q2 2020, following safety data from the ongoing Phase 1 study.In addition, Moderna will now hire up to 150 new team members to support efforts following …read more
Source:: Yahoo Finance
